However, CHOP-based chemotherapy has scarce efficacy in PEL, and more intensive chemotherapeutic protocols, such as EPOCH, or treatments targeting the proteasome, the NF-kB pathway or anti-CD30 therapy are required [14,73]. The gene discussed is TNFRSF8; the disease is primary effusion lymphoma.